• Inflammatory biomarkers in newly diagnosed patients with Parkinson’s disease and related neurodegenerative disorders 

      Pedersen, Camilla Christina; Ushakova, Anastasia; Skogseth, Ragnhild Eide; Alves, Guido Werner; Tysnes, Ole-Bjørn; Aarsland, Dag; Lange, Johannes; Maple-Grødem, Jodi (Journal article; Peer reviewed, 2023)
      Background and Objectives Neuroinflammation contributes to Parkinson disease (PD) pathology, and inflammatory biomarkers may aid in PD diagnosis. Proximity extension assay (PEA) technology is a promising method for multiplex ...
    • Neurofilament light chain predicts disease activity in relapsing-remitting MS 

      Varhaug, Kristin Nielsen; Barro, Christian; Bjørnevik, Kjetil Lauvland; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig; Bindoff, Laurence; Kuhle, Jens; Vedeler, Christian A. (Peer reviewed; Journal article, 2018)
      Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort of 85 patients with RRMS were followed ...
    • No association of tobacco use and disease activity in multiple sclerosis 

      Kvistad, Silje; Myhr, Kjell-Morten; Holmøy, Trygve; Saltyte Benth, Jurate; Løken-Amsrud, Kristin Ingeleiv; Wergeland, Stig; Beiske, Antonie Giæver; Bjerve, Kristian S; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Bakke, Søren Jacob; Torkildsen, Øivind (Peer reviewed; Journal article, 2016-08)
      Objective: To study whether tobacco use is associated with MRI and clinical disease activity in patients with multiple sclerosis (MS). Methods: Prospective cohort study of 87 patients with relapsing-remitting MS originally ...
    • Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy 

      Bringeland, Gerd Haga; Blaser, Nello; Myhr, Kjell-Morten; Vedeler, Christian A.; Gavasso, Sonia (Journal article; Peer reviewed, 2020-02)
      Objective: We aimed to investigate whether wearing-off symptoms at the end of the natalizumab dosing interval were associated with clinical and demographic patient characteristics or natalizumab receptor occupancy (RO) on ...